loading...| Preferred Name |
mifepristone |
|
| Synonyms |
Mifeprex |
|
| Definitions |
A derivative of the synthetic progestin norethindrone with antiprogesterone activity. Mifepristone competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C655" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C655" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000040888 |
|
| altLabel |
Mifeprex 11-((4-dimethylamino) phenyl)-17-Hydroxy-17-(1-propynyl) estra-4,9- dien-3-one Mifegyne RU-38486 RU486 RU 486 (aa Beta, 17 beta)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one 11 beta-[4-(N,N-dimethylamino)phenyl]-17alpha-(propyl-1-ynyl)-delta-4,9-estradiene-17 beta-ol-3-one RU-486 |
|
| CAS Registry |
84371-65-3 |
|
| cui |
C0701303 C0591786 C0939382 C0026088 |
|
| Date last modified |
2008-02-19 |
|
| definition |
A derivative of the synthetic progestin norethindrone with antiprogesterone activity. Mifepristone competitively binds to the progesterone receptor, resulting in inhibition of the effects of endogenous or exogenous progesterone. This agent also exhibits antiglucocorticoid and weak antiandrogenic activities. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C655" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C655" NCI Thesaurus) |
|
| Legacy PDQ ID |
3926 |
|
| LT |
TRD |
|
| NCI ID |
C655 |
|
| notation |
CDR0000040888 |
|
| NSC Code |
652104 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
mifepristone |
|
| tui |
T109 T121 |